Abstract | BACKGROUND:
Vogt-Koyanagi-Harada syndrome (VKH) is a multisystem disorder, characterized by the T-cell-mediated autoimmune process directed against melanocytic antigens in the ocular, nervous, auditory and integumentary systems. The ocular hallmarks of the disease involve severe bilateral panuveitis associated with exudative retinal detachment. CASE REPORT: INTERVENTION: CONCLUSION: We recommend use of ocular invasive treatment modalities in Vogt-Koyanagi-Harada Syndrome only if the disease progression cannot be controlled. If systemic medications fail to stop the progression of the disease activity, subtenon injections may be considered before intraocular treatment modalities.
|
Authors | Irfan Perente, Canan Asli Utine, Hanefi Cakir, Vedat Kaya, Ilknur Tugal Tutkun, Omer Faruk Yilmaz |
Journal | International ophthalmology
(Int Ophthalmol)
Vol. 29
Issue 1
Pg. 33-7
(Feb 2009)
ISSN: 1573-2630 [Electronic] Netherlands |
PMID | 17952373
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Glucocorticoids
- Immunosuppressive Agents
- Cyclosporine
- Triamcinolone Acetonide
|
Topics |
- Adolescent
- Cyclosporine
(therapeutic use)
- Drug Therapy, Combination
- Eye Diseases
(diagnostic imaging, drug therapy, etiology)
- Female
- Fluorescein Angiography
- Glucocorticoids
(therapeutic use)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Optic Nerve Diseases
(diagnostic imaging, drug therapy, etiology)
- Retinal Detachment
(diagnostic imaging, drug therapy, etiology)
- Tomography, Optical Coherence
- Triamcinolone Acetonide
(therapeutic use)
- Ultrasonography
- Uveomeningoencephalitic Syndrome
(complications, diagnostic imaging, drug therapy)
- Vitreous Body
(diagnostic imaging, pathology)
|